Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ripasudil in preparation of medicine for treating bacterial infection

A technology for risudil and bacterial infection, applied in the field of medicine to achieve the effect of improving organ damage

Active Publication Date: 2021-08-17
HANGZHOU FIRST PEOPLES HOSPITAL
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there has not been any report on the application of lisudil in the prevention and treatment of bacterial infections

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ripasudil in preparation of medicine for treating bacterial infection
  • Application of ripasudil in preparation of medicine for treating bacterial infection
  • Application of ripasudil in preparation of medicine for treating bacterial infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] In order to verify the role of lisudil in the treatment of E.coli infection, E.coli was used to infect the abdominal cavity of mice to construct a sepsis mouse model; the sepsis mice were divided into 3 different doses (5mg / kg , 10mg / kg and 20mg / kg) lisudil treatment group and negative control group, after 5 minutes of E.coli infection in mouse abdominal cavity, give 5mg / kg, 5mg / kg, 10mg / kg and 20mg / kg of risudil, and the negative control group mice were given the same dose of solvent (distilled water) intraperitoneally; choose healthy mice at the same time, set the blank control group and risudil control group, wherein, Lisudil 20 mg / kg was administered intraperitoneally to the mice in the lisudil control group, and the same dose of solvent (distilled water) was administered to the mice in the blank control group. Observe the 72h survival rate of each group of mice, the observation results are shown in figure 1 .

[0055] Depend on figure 1 It can be seen that the 7...

Embodiment 2

[0057] Adopt the same method as Example 1 to construct the sepsis mouse model, and set the same Lisudil treatment group (5mg / kg, 10mg / kg and 20mg / kg), negative control group and blank control group as in Example 1 group and lisudil control group (5mg / kg, 10mg / kg and 20mg / kg) mice, each group of four mice; after detection of abdominal cavity E.coli infection 12h, alanine aminotransferase (ALT ), aspartate aminotransferase (AST), creatinine (CREA), blood urea nitrogen (BUN) concentration levels, the test results are shown in sequence figure 2 , image 3 , Figure 4 and Figure 5 .

[0058] Depend on figure 2 , image 3 , Figure 4 and Figure 5 It can be seen that the ALT level, AST level, CREA level and BUN level of the mice in each lisudil control group are equivalent to those of the blank control group, indicating that lisudil has no toxic effect on mice and does not cause liver and kidney damage.

[0059] Depend on figure 2 It can be seen that after 12 hours of i...

Embodiment 3

[0069] Adopt the same method as Example 1 to construct the sepsis mouse model, and set the same Lisudil treatment group (20mg / kg), negative control group, blank control group and Lisudil control group as Example 1 (Mice, after detection of E.coli infection in the abdominal cavity for 12 hours, the bacterial load in the blood and peritoneal lavage fluid of each group of mice, and on the liver, lung, spleen and kidney, the test results are shown in Table 2, Figure 10 , Figure 11 , Figure 12 , Figure 13 , Figure 14 and Figure 15 shown.

[0070] Table 2

[0071]

[0072] From Table 2, Figure 10 , Figure 11 , Figure 12 , Figure 13 , Figure 14 and Figure 15 It can be seen that the administration of lisudil after E.coli infection in the abdominal cavity can significantly reduce the bacterial load in the blood, abdominal cavity and various organs of septic mice.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of ripasudil in preparation of a medicine for treating bacterial infection. It is found for the first time that the ripasudil can significantly reduce the expression level of inflammatory factors (TNF-alpha and IL-1beta) in serum and abdominal lavage fluid of mice infected with bacteria and effectively improve the survival rate of the mice infected with bacteria (including escherichia coli, acinetobacter baumannii, streptococcus pneumoniae and the like), which prompts that the ripasudil has a good function of inhibiting inflammatory pathways, can be used for treating bacterial infection and provides a new way for treatment of bacterial infection.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to the application of lisudil in the preparation of medicines for treating bacterial infections. Background technique [0002] Bacterial infection is an acute systemic infection caused by pathogenic bacteria or conditional pathogenic bacteria invading the blood circulation from wounds or internal infection lesions to produce toxins and other metabolites. It is characterized by splenomegaly, and some patients may have septic shock and migratory lesions; clinically, some patients may also experience irritability, cold extremities and cyanosis, thready and rapid pulse, rapid breathing, and decreased blood pressure. Especially the elderly, children, those with chronic diseases or immunocompromised, untimely treatment and those with complications may develop sepsis. [0003] The key to the treatment of bacterial infection lies in the timely and appropriate selection of ant...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/496A61P31/04
CPCA61K31/496A61P31/04Y02A50/30
Inventor 王汉斌罗赣徐之鹏张珏吴虹霞
Owner HANGZHOU FIRST PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com